ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 52.16B
Enterprise Value 31.89B
Trailing P/E N/A
Forward P/E 1-6.95
PEG Ratio (5 yr expected) 10.69
Price/Sales (ttm)9.89
Price/Book (mrq)12.35
Enterprise Value/Revenue 38.65
Enterprise Value/EBITDA 6-6.74

Trading Information

Stock Price History

Beta (3Y Monthly) 1.04
52-Week Change 3-35.95%
S&P500 52-Week Change 32.33%
52 Week High 3133.74
52 Week Low 358.21
50-Day Moving Average 368.44
200-Day Moving Average 389.62

Share Statistics

Avg Vol (3 month) 3605.03k
Avg Vol (10 day) 3394.78k
Shares Outstanding 529.79M
Float 25.81M
% Held by Insiders 124.22%
% Held by Institutions 172.67%
Shares Short (Jul 31, 2019) 45.1M
Short Ratio (Jul 31, 2019) 47.7
Short % of Float (Jul 31, 2019) 427.93%
Short % of Shares Outstanding (Jul 31, 2019) 415.61%
Shares Short (prior month Jun 28, 2019) 45.71M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -143.57%
Operating Margin (ttm)-131.55%

Management Effectiveness

Return on Assets (ttm)-24.68%
Return on Equity (ttm)-195.26%

Income Statement

Revenue (ttm)218.82M
Revenue Per Share (ttm)7.27
Quarterly Revenue Growth (yoy)52.20%
Gross Profit (ttm)177.28M
EBITDA -281.1M
Net Income Avi to Common (ttm)-314.15M
Diluted EPS (ttm)-10.44
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)758.52M
Total Cash Per Share (mrq)23.2
Total Debt (mrq)559.08M
Total Debt/Equity (mrq)319.11
Current Ratio (mrq)6.54
Book Value Per Share (mrq)5.36

Cash Flow Statement

Operating Cash Flow (ttm)-233.77M
Levered Free Cash Flow (ttm)-115.52M